研究者業績

鈴木 達也

Suzuki Tatsuya

基本情報

所属
藤田医科大学 医学部 医学科 小児外科学 教授
学位
博士(医学)

J-GLOBAL ID
200901042339226272
researchmap会員ID
5000030080

論文

 117
  • Mika Murayama, Toshihiro Yasui, Mikihiro Inoue, Shunsuke Watanabe, Atsuki Naoe, Yasuhiro Kondo, Tomonori Tsuchiya, Tatsuya Suzuki
    Clinical and experimental hepatology 10(2) 98-103 2024年3月  
    AIM OF THE STUDY: This study aimed to establish an objective, simple, and minimally invasive screening method to detect patients with biliary atresia during neonatal checkups by using indocyanine green (ICG) fluorescence in the stool. MATERIAL AND METHODS: We produced a rat model of extrahepatic biliary obstruction (group O, n = 9) and compared the stools from these rats with those of control group rats (group C, n = 6) by a fluorescence technique. ICG was administered (0.5 mg/kg) through the caudal vein; group O received ICG at the end of surgery. RESULTS: In group C, we collected stools at 3, 6, 12, 24, 48, and 72 hours, and fluorescence disappeared at 48 hours. In group O, stools were collected at 24, 48, 72, 96, and 120 hours after surgery, and fluorescence continued at 120 hours without the loss of fluorescence. Quantitative assessment of lightness showed significant differences between the groups at 48 and 72 hours (p = 0.0016 and p = 0.0004, respectively). CONCLUSIONS: This study shows that ICG is excreted into the gastrointestinal tract via a route other than the bile duct in a rat model of extrahepatic biliary obstruction. Our findings also suggest that ICG has the potential for initial screening of biliary congestive disease in the neonatal period, which could be followed up by detailed testing.
  • Shunsuke Watanabe, Mikihiro Inoue, Tatsuya Suzuki, Yasuhiro Kondo, Mika Murayama
    Pediatric surgery international 39(1) 196-196 2023年5月9日  
    BACKGROUND: We previously reported that polyphyllin D, the main component of the traditional herbal medicinal Paris polyphylla, exhibited anticancer effects in vitro against human neuroblastoma cells. The aim of this investigation was to examine in vivo antitumor effects of polyphyllin D. METHODS: Subcutaneous tumors were established in immune-deficient BALB/c nude mice using human neuroblastoma cell lines IMR-32 and LA-N-2. To evaluate the polyphyllin D activity, we used a mouse model of IMR-32 or LA-N-2 cell lines and analyzed subcutaneous tumors. RESULTS: Subcutaneous tumor models were successfully established in mice using two human neuroblastoma cell lines. In the subcutaneous tumor model, porphyrin D was found to suppress tumor volume. We found that polyphyllin D suppressed the number of foci by Ki-67 staining (IMR-32 and LA-N-2; p < 0.01, 0.02, respectively). We found that polyphyllin D induces the RIPK3 expression, while polyphyllin D phosphorylates Ser358 in IMR-32 and Ser358 and Tyr376 in LA-N-2. CONCLUSION: We developed a mouse model of subcutaneous tumors of neuroblastoma and demonstrated for the first time that polyphyllin D has an antitumor effect on neuroblastoma. Polyphyllin D can cause necroptosis depending on the cell type. The new drug can be expected by investigating a method to selectively induce cell death through the analysis of necroptosis.
  • 渡邉 俊介, 井上 幹大, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 安井 稔博, 鈴木 達也
    日本小児血液・がん学会雑誌 59(2) 211-211 2022年7月  
  • 土屋 智寛, 村山 未佳, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 井上 幹大, 鈴木 達也
    日本小児外科学会雑誌 58(2) 209-209 2022年4月  
  • 直江 篤樹, 安井 稔博, 土屋 智寛, 村山 未佳, 近藤 靖浩, 渡邉 俊介, 井上 幹大, 鈴木 達也
    日本小児外科学会雑誌 58(2) 210-210 2022年4月  
  • 渡邉 俊介, 井上 幹大, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 安井 稔博, 鈴木 達也
    日本小児外科学会雑誌 58(3) 558-558 2022年4月  
  • 安井 稔博, 土屋 智寛, 村山 未佳, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 井上 幹大, 鈴木 達也
    日本小児外科学会雑誌 58(3) 566-566 2022年4月  
  • 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 井上 幹大, 鈴木 達也
    日本小児外科学会雑誌 58(3) 590-590 2022年4月  
  • 近藤 靖浩, 土屋 智寛, 村山 未佳, 直江 篤樹, 渡邉 俊介, 安井 稔博, 井上 幹大, 鈴木 達也
    日本小児外科学会雑誌 58(3) 667-667 2022年4月  
  • 土屋 智寛, 村山 未佳, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 井上 幹久, 鈴木 達也
    日本小児外科学会雑誌 58(3) 676-676 2022年4月  
  • Shunsuke Watanabe, Tatsuya Suzuki, Tomonori Tsuchiya, Yasuhiro Kondo
    Asian journal of surgery 45(3) 849-853 2022年3月  
    BACKGROUND: Biliary atresia (BA) is a rare disorder characterized by obstructive jaundice in infants, shortly after birth. Postoperatively, some patients exhibit portal hypertension and progressive liver fibrosis. Splenomegaly is a symptom of portal hypertension. We aimed to investigate splenomegaly as a marker for complications of portal hypertension and the relationship between splenomegaly and liver fibrosis in the long-term native liver (NL). METHODS: Between 1977 and 2018, 71 patients underwent hepaticojejunostomy. We included 54 patients (34 NL group, 20 liver transplant (LT) group) who fulfilled the eligibility criteria. Spleen volume (SV), total bile acids, hyaluronic acid, type IV collagen, and aspartate aminotransferase-to-platelet ratio index (APRi) were measured. Data were analyzed using Student's t-test, regression analysis, and receiver operating characteristic (ROC) curve analysis (P < 0.05). RESULTS: Total bile acids, hyaluronic acid, type IV collagen, and APRi increased in NL patients with a large SV at >25 years. SV and type IV collagen were correlated with NL for >25 years (r = 0.79 [P = 0.006], y = 1.1 - [0.03 × type IV collagen] [P = 0.008]). In the ROC curve analysis, the cutoff value for type IV collagen was 165 ng/mL (P = 0.07). CONCLUSIONS: We suggest that SV as a prognostic index for End-Stage Liver Disease may be useful in biliary atresia. Long-term follow-up is necessary because the clinical course may be favorable in childhood but worsen during adulthood.
  • Tomonori Tsuchiya, Mikihiro Inoue, Toshihiro Yasui, Tatsuya Suzuki
    Pediatrics international : official journal of the Japan Pediatric Society 64(1) e15307 2022年1月  
  • Yutaro Kato, Atsushi Sugioka, Masayuki Kojima, Junichi Yoshikawa, Yoshinao Tanahashi, Sanae Nakajima, Akira Yasuda, Gozo Kiguchi, Yuichiro Uchida, Toshihiro Yasui, Tatsuya Suzuki, Hokuto Akamatsu, Ryota Hanaoka, Hiroyuki Nagata, Ryoichi Kato, Ichiro Uyama
    Surgical Case Reports 7(1) 2021年12月  
    <title>Abstract</title><sec> <title>Background</title> Acute obstruction of the hepatic vein (HV) or the portal vein (PV), particularly when it occurs during liver surgery, is potentially fatal unless repaired swiftly. As surgical interventions for this problem are technically demanding and potentially unsuccessful, other treatment options are needed. </sec><sec> <title>Case presentation</title> We report two cases of acute, surgically uncorrectable HV or PV obstruction during liver resection or living donor liver transplantation (LDLT), which was successfully treated with urgent intraoperative placement of endovascular stents using interventional radiology (IVR). In Case 1, a patient with colonic liver metastases underwent a non-anatomic partial hepatectomy of the segments 4 and 8 with middle hepatic vein (MHV) resection. Additionally, the patient underwent an extended right posterior sectionectomy with right hepatic vein (RHV) resection for tumors involving RHV. Reconstruction of the MHV was needed to avoid HV congestion of the anterior section of the liver. The MHV was firstly reconstructed by an end-to-end anastomosis between the MHV and RHV resected stumps. However, the reconstruction failed to retain the HV outflow and the anterior section became congested. Serial trials of surgical revisions including re-anastomosis, vein graft interposition and vein graft patch-plasty on the anastomotic wall failed to recover the HV outflow. In Case 2, a pediatric patient with biliary atresia underwent an LDLT and developed an intractable PV obstruction during surgery. Re-anastomosis with vein graft interposition failed to restore the PV flow and elongated warm ischemic time became critical. In both cases, the misalignment in HV or PV reconstruction was likely to have caused flow obstruction, and various types of surgical interventions failed to recover the venous flow. In both cases, an urgent IVR-directed placement of self-expandable metallic stents (SEMS) restored the HV or PV perfusion quickly and effectively, and saved the patients from developing critical conditions. Furthermore, in Cases 1 and 2, the SEMS placed were patent for a sufficient period of time (32 and 44 months, respectively). </sec><sec> <title>Conclusions</title> The IVR-directed, urgent, intraoperative endovascular stenting is a safe and efficient treatment tool that serves to resolve the potentially fatal acute HV or PV obstruction that occurs in the middle of liver surgery. </sec>
  • 安井 稔博, 土屋 智寛, 村山 未佳, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 井上 幹大, 鈴木 達也
    移植 56(総会臨時) P1-11 2021年9月  
  • 直江 篤樹, 鈴木 達也, 安井 稔博, 井上 幹大, 渡邉 俊介, 近藤 靖浩, 土屋 智寛, 村山 未佳
    移植 56(総会臨時) P2-6 2021年9月  
  • 直江 篤樹, 土屋 智寛, 村山 未佳, 近藤 靖浩, 渡邉 俊介, 安井 稔博, 鈴木 達也
    小児外科 53(6) 644-646 2021年6月  
  • 鈴木 達也, 橋本 俊, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 宇賀 菜緒子, 渡邉 俊介, 安井 稔博, 原 普二夫
    日本小児外科学会雑誌 57(4) 793-793 2021年6月  
  • 田中 真己人, 三浦 浩樹, 小澤 慶, 石丸 聡一郎, 河村 吉紀, 吉川 哲史, 工藤 寿子, 渡邉 俊介, 安井 稔博, 村山 未佳, 土屋 智寛, 近藤 靖浩, 宇賀 菜緒子, 直江 篤樹, 原 普二夫, 鈴木 達也, 山田 勢至, 浦野 誠
    日本小児血液・がん学会雑誌 58(1) 65-66 2021年6月  
  • 田中 真己人, 三浦 浩樹, 小澤 慶, 石丸 聡一郎, 河村 吉紀, 吉川 哲史, 工藤 寿子, 渡邉 俊介, 安井 稔博, 村山 未佳, 土屋 智寛, 近藤 靖浩, 宇賀 菜緒子, 直江 篤樹, 原 普二夫, 鈴木 達也, 山田 勢至, 浦野 誠
    日本小児血液・がん学会雑誌 58(1) 65-66 2021年6月  
  • 安井 稔博, 土屋 智寛, 村山 未佳, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 鈴木 達也, 宇賀 菜緒子
    日本小児外科学会雑誌 57(2) 386-386 2021年4月  
  • 近藤 靖浩, 鈴木 元, 浅井 直也, 竹内 俊幸, 土屋 智寛, 村山 未佳, 宇賀 菜緒子, 直江 篤樹, 渡邉 俊介, 安井 稔博, 鈴木 達也
    日本小児外科学会雑誌 57(2) 388-388 2021年4月  
  • 直江 篤樹, 土屋 智寛, 村山 美佳, 宇賀 菜緒子, 近藤 靖浩, 渡邉 俊介, 安井 稔博, 鈴木 達也
    日本小児外科学会雑誌 57(2) 451-451 2021年4月  
  • 渡邉 俊介, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 宇賀 菜緒子, 安井 稔博, 鈴木 達也
    日本小児外科学会雑誌 57(2) 506-506 2021年4月  
  • 宇賀 菜緒子, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 鈴木 達也, 常陸 圭介, 土田 邦博, 吉村 文, 熊本 海生航, 長尾 静子
    日本小児外科学会雑誌 57(2) 390-390 2021年4月  
  • 宇賀 菜緒子, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 鈴木 達也, 常陸 圭介, 土田 邦博, 吉村 文, 熊本 海生航, 長尾 静子
    日本小児外科学会雑誌 57(2) 390-390 2021年4月  
  • 村山 未佳, 土屋 智寛, 宇賀 菜緒子, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 原 普二夫, 鈴木 達也
    日本小児外科学会雑誌 57(1) 77-77 2021年2月  
  • 渡邉 俊介, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 宇賀 菜緒子, 安井 稔博, 原 普二夫, 鈴木 達也
    日本小児血液・がん学会雑誌 57(5) 412-412 2021年2月  
  • Yutaro Kato, Atsushi Sugioka, Yoshinao Tanahashi, Masayuki Kojima, Sanae Nakajima, Akira Yasuda, Junichi Yoshikawa, Toshihiro Yasui, Tatsuya Suzuki, Ichiro Uyama
    Liver Transplantation 27(2) 291-295 2021年2月  
  • Naoko Uga, Masashi Nakatani, Aya Yoshimura, Kanako Kumamoto, Kunihiro Tsuchida, Shizuko Nagao, Tomonori Tsuchiya, Yasuhiro Kondo, Atsuki Naoe, Shunsuke Watanabe, Toshihiro Yasui, Fujio Hara, Tatsuya Suzuki
    Fujita medical journal 7(2) 41-49 2021年  
    Objectives: Proximal stoma creation in neonates results in growth failure and distal intestinal atrophy. "Recycling stool" consists of stool injection from the proximal limb to the distal limb of a stoma. Because this method may prevent distal bowel atrophy and increase body weight, we investigated the effects of recycling stool upon distal intestinal mucosa by generating an ileostomy model in rats. Methods: An ileostomy was created 5 cm proximal to the cecum in male Wistar/ST rats. Discharged stool or saline was injected into the distal limb, twice per day for 7 days. The intestinal adaptation was assessed by measuring the villus height and counting goblet cell number. Proliferation and apoptosis were analyzed by Ki67 and TUNEL immunostaining. Results: The ratios of the height of the distal villi (D) to the that of proximal villi (P) were 0.97 (median [range] of D and P length: 421 [240-729] μm and 436 [294-638] μm, P<0.05) in the stool-injected group and 0.81 in the saline-injected group (442 [315-641] μm and 548 [236-776] μm, P<0.05). Compared with the saline-injected group, the stool-injected group showed elevated numbers of goblet cells (3.6 [2.0-7.6] vs. 4.9 [2.4-7.5] cells/100-μm villus length) and Ki67-positive cells (26.8% [13.8%-35.4%] vs. 40.1% [31.2%-45.7%]), along with a reduced number of apoptotic cells (5.0 [2.0-14.0] vs. 4.0 [1.0-9.0] cells/100-μm villus length). Conclusions: Recycling stool prevented distal intestinal atrophy; this experimental design may facilitate further studies concerning alternative methods to prevent intestinal atrophy and growth failure.
  • 渡邉 俊介, 伊藤 昌広, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 宇賀 菜緒子, 安井 稔博, 鈴木 達也
    日本小児血液・がん学会雑誌 57(4) 258-258 2020年10月  
  • 直江 篤樹, 土屋 智寛, 村山 美佳, 宇賀 菜緒子, 近藤 靖浩, 渡邉 俊介, 安井 稔博, 原 普二夫, 冨重 博一, 鈴木 達也
    日本小児外科学会雑誌 56(5) 689-689 2020年9月  
  • 村山 未佳, 土屋 智寛, 宇賀 菜緒子, 直江 篤樹, 近藤 靖浩, 渡邉 俊介, 安井 稔博, 原 普二夫, 鈴木 達也
    日本小児外科学会雑誌 56(5) 747-747 2020年9月  
  • 宇賀 菜緒子, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 鈴木 達也
    日本小児外科学会雑誌 56(5) 776-776 2020年9月  
  • 安井 稔博, 土屋 智寛, 村山 美佳, 宇賀 菜緒子, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 原 普二夫, 鈴木 達也
    日本小児外科学会雑誌 56(5) 781-781 2020年9月  
  • 渡邉 俊介, 村山 未佳, 土屋 智寛, 近藤 靖浩, 宇賀 菜緒子, 直江 篤樹, 安井 稔博, 鈴木 達也
    日本小児外科学会雑誌 56(5) 824-824 2020年9月  
  • 渡邉 俊介, 原 普二夫, 安井 稔博, 宇賀 菜緒子, 直江 篤樹, 近藤 靖浩, 土屋 智寛, 鈴木 達也
    日本小児血液・がん学会雑誌 57(1) 24-27 2020年6月  
  • 村山 未佳, 鈴木 達也, 原 普二夫, 安井 稔博, 渡邉 俊介, 宇賀 菜緒子, 近藤 靖浩, 直江 篤樹, 土屋 智寛
    日本小児外科学会雑誌 56(2) 232-232 2020年4月  
  • 土屋 智寛, 鈴木 達也, 原 普二夫, 安井 稔博, 渡邉 俊介, 宇賀 菜緒子, 直江 篤樹, 近藤 靖浩, 村山 未佳
    日本小児外科学会雑誌 56(2) 232-233 2020年4月  
  • 宇賀 菜緒子, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 隆樹, 渡邉 俊介, 安井 稔博, 原 普二夫, 山田 勢至, 浦野 誠, 鈴木 達也
    日本小児外科学会雑誌 56(2) 233-233 2020年4月  
  • 渡邉 俊介, 村山 未佳, 土屋 智寛, 宇賀 菜緒子, 近藤 靖浩, 直江 篤樹, 安井 稔博, 原 普二夫, 鈴木 達也
    日本小児外科学会雑誌 56(2) 236-236 2020年4月  
  • Shunsuke Watanabe, Fujio Hara, Toshihiro Yasui, Tomonori Tsuchiya, Tatsuya Suzuki
    Indian Journal of Surgery 2020年  
  • 安井 稔博, 鈴木 達也, 原 普二夫, 渡邉 俊介, 宇賀 菜緒子, 近藤 靖浩, 直江 篤樹, 土屋 智寛
    日本小児外科学会雑誌 55(7) 1164-1169 2019年12月  
  • 安井 稔博, 鈴木 達也, 原 普二夫, 渡邉 俊介, 宇賀 菜緒子, 近藤 靖浩, 直江 篤樹, 土屋 智寛
    日本小児外科学会雑誌 55(7) 1164-1169 2019年12月  査読有り
  • 安井 稔博, 近藤 靖浩, 直江 篤樹, 渡邊 俊介, 原 普二夫, 鈴木 達也
    移植 54(総会臨時) 268-268 2019年9月  
  • 鈴木 達也, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 宇賀 菜緒子, 渡邉 俊介, 安井 稔博, 原 普二夫
    日本小児外科学会雑誌 55(5) 1010-1010 2019年8月  査読有り
  • 渡邉 俊介, 土屋 智寛, 宇賀 菜緒子, 近藤 靖浩, 直江 篤樹, 安井 稔博, 原 普二夫, 鈴木 達也
    日本小児外科学会雑誌 55(5) 1013-1014 2019年8月  査読有り
  • 直江 篤樹, 土屋 智寛, 近藤 靖浩, 宇賀 菜緒子, 渡邉 俊介, 安井 稔博, 原 普二夫, 鈴木 達也
    日本小児外科学会雑誌 55(3) 533-533 2019年5月  
  • 安井 稔博, 土屋 智寛, 宇賀 菜緒子, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 原 普二夫, 鈴木 達也
    日本小児外科学会雑誌 55(3) 538-538 2019年5月  
  • 土屋 智寛, 近藤 靖浩, 宇賀 菜緒子, 直江 篤樹, 渡邉 俊介, 安井 稔博, 原 普二夫, 鈴木 達也
    日本小児外科学会雑誌 55(3) 695-695 2019年5月  
  • 宇賀 菜緒子, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 原 普二夫, 鈴木 達也, 中谷 直史, 土田 邦博, 吉村 文, 熊本 海生航, 長尾 静子
    日本小児外科学会雑誌 55(3) 674-674 2019年5月  

MISC

 33
  • 近藤靖浩, 安井稔博, 土屋智寛, 村山未佳, 直江篤樹, 渡邉俊介, 井上幹大, 鈴木達也
    日本小児外科学会雑誌 59(3) 2023年  
  • 近藤靖浩, 土屋智寛, 村山未佳, 直江篤樹, 渡邉俊介, 安井稔博, 井上幹大, 鈴木達也
    日本胆道閉鎖症研究会プログラム・演題抄録集 49th 2022年  
  • Atsuki Naoe, Tomonori Tsuchiya, Yasuhiro Kondo, Naoko Uga, Shunsuke Watanabe, Toshihiro Yasui, Fujio Hara, Tatsuya Suzuki
    Pediatric surgery international 35(6) 723-728 2019年6月  
    PURPOSE: Arctigenin has been shown to have anti-tumor effects in various types of cancers. This study was conducted to verify these effects in the human-derived hepatoblastoma cell line, HUH-6 clone 5 (hereinafter, HUH-6). METHODS: Arctigenin was added to cultured HUH-6 cells, and cellular activity was evaluated by MTS assay. To determine the relationship between reduced cellular activity and apoptosis, we measured the activities of caspase 3/7, 8, and 9 and conducted flow cytometry with Annexin V/PI staining. RESULTS: The MTS assay revealed that cellular activity decreased after arctigenin treatment in a concentration-dependent manner (IC50 = 4 µM). To investigate apoptosis induction, activity assays of caspase 3/7, 8, and 9 were performed. While caspase 3/7 and 8 exhibited high activity, caspase 9 showed no activity. Thus, apoptosis induction may have involved the action of tumor necrosis factor receptor 1 (TNFR1). Flow cytometry conducted with Annexin V/PI staining revealed the occurrence of early apoptosis. CONCLUSION: We found that arctigenin has anti-tumor effects in HUH-6 cells in a concentration-dependent manner. Arctigenin may have exerted its anti-tumor effect by inducing apoptosis via TNFR1, which recruits Complex IIa to activate caspase 8 and 3/7. These results may be useful for developing therapeutic agents for hepatoblastoma.
  • 宇賀 菜緒子, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 原 普二夫, 鈴木 達也, 中谷 直史, 土田 邦博, 吉村 文, 熊本 海生航, 長尾 静子
    日本小児外科学会雑誌 55(3) 674-674 2019年5月  
  • Shunsuke Watanabe, Tatsuya Suzuki, Yasuhiro Kondo, Atsuki Naoe, Naoko Uga, Toshihiro Yasui, Fujio Hara, Tomonori Tsuchiya
    Minerva pediatrica 2019年1月2日  
    BACKGROUND: Neuroblastoma (NB) is a pediatric malignant solid tumor characterized as refractory cancer with poor prognosis. Mitosis-karyorrhexis index (MKI) is a prognostic factor but is prone to observer bias. The usefulness of MKI with Ki-67, as a marker of malignancy, was investigated. The efficacy of molecular-targeted therapeutic agents with fewer side effects in tumors has been studied. Molecular-targeted therapy targets include vascular endothelial growth factor (VEGF), involved in tumor angiogenesis; c-Kit, receptor of Kit/stem cells involved in tumor growth, vasculature, and lymphangiogenesis; platelet-derived growth factor receptor (PDGFR); and B-Raf proto-oncogene, serine/threonine kinase (BRAF), involved in the RAS protein-mediated mitogen-activated protein kinase pathway. Therefore, expression profiles of these factors and growth inhibitory effects of molecular-targeted drugs against NB were investigated. METHODS: Ten frozen NB tissue samples collected during January 1993-December 2017 were evaluated immunohistochemically for Ki-67 and VEGF. c-Kit, PDGFR, and BRAF expression levels were evaluated using enzyme-linked immunosorbent assays; relationships between these factors and clinicopathological parameters of NB were analyzed. RESULTS: Eight patients with NB showed no amplification of MYCN (MYCN proto- oncogene, bHLH transcription factor). There were two cases of ganglioneuroblastoma (GNB). More NB cells were positive for Ki-67 than for GNB cells. VEGF expression was observed in all NB specimens and was stronger in stage IIB and higher. No BRAF or c-Kit activity was observed; PDGFR activity was greater in NB than in GNB (p = 0.02). CONCLUSIONS: Thus, Ki-67 may help evaluate NB malignancy. As the first therapy for NB prevents amplification of MYCN, agents targeting PDGFR as well as VGFG can inhibit NB cell proliferation.

書籍等出版物

 7

講演・口頭発表等

 26

共同研究・競争的資金等の研究課題

 4